Devonian Announces the Results of its Annual General and Special Shareholders’ Meeting, the Approval of Amendments to its Stock Option Plan, and Grant of Stock Options
PRESS RELEASE For immediate release Devonian Announces the Results of its Annual General and Special Shareholders' Meeting, the Approval of Amendments to its Stock Option Plan, and Grant of Stock Options Not for distribution to United States newswire services or for...
DEVONIAN BOLSTERS INTELLECTUAL PROPERTY WITH ISSUANCE OF U.S. PATENT COVERING A METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE
PRESS RELEASEFor immediate release DEVONIAN BOLSTERS INTELLECTUAL PROPERTY WITH ISSUANCE OF U.S. PATENT COVERING A METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE QUÉBEC, Québec – February 20, 2024 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV:...
Devonian Seeks Shareholders Approval for Share Consolidation
PRESS RELEASEFor immediate release Devonian Seeks Shareholders Approval for Share Consolidation QUEBEC, January 19, 2024 - Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation,...
Devonian Bolsters Leadership Team and Aligns Strategy to Accelerate Clinical Development and Drive Revenue Growth and Commercial Success
PRESS RELEASE For immediate release Devonian Bolsters Leadership Team and Aligns Strategy to Accelerate Clinical Development and Drive Revenue Growth and Commercial Success Luc Grégoire, current Director of Devonian, appointed as President and CEO, brings 30 years of...
Devonian files Patent Cooperation Treaty (PCT) application for Thykamine™ in wound healing
PRESS RELEASE For immediate release Devonian files Patent Cooperation Treaty (PCT) application for Thykamine™ in wound healing QUÉBEC, Québec – November 8, 2023 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage...
Devonian Announces Closing of a Private Placement of $500,000
PRESS RELEASE For immediate release Devonian Announces Closing of a Private Placement of $500,000 Not for distribution to United States newswire services or for dissemination in the United States QUEBEC, September 1, 2023 – Devonian Health Group Inc. (“Devonian” or...
Devonian Health Group receives a Notice of Allowance for Issuance of a U.S. Patent on a method of treatment of Inflammatory Bowel Disease.
PRESS RELEASE For immediate release Devonian Health Group receives a Notice of Allowance for Issuance of a U.S. Patent on a method of treatment of Inflammatory Bowel Disease. QUEBEC, – June 20, 2023 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV:...
Devonian Announces Closing of a Private Placement of $1.2 Million
PRESS RELEASE For immediate release Devonian Announces Closing of a Private Placement of $1.2 Million Not for distribution to United States newswire services or for dissemination in the United States QUEBEC, June 6, 2023 – Devonian Health Group Inc. (“Devonian” or the...
Devonian Announces Private Placement of up to $5 Million
PRESS RELEASE For immediate release Devonian Announces Private Placement of up to $5 Million. Not for distribution to United States newswire services or for dissemination in the United States QUEBEC, May 19, 2023 – Devonian Health Group Inc. (“Devonian” or the...
Devonian Health Group announces presentation of Thykamine™ efficacy results in Atopic Dermatitis at the World Congress of Dermatology and provides Thykamine™ Clinical Development Program Update.
PRESS RELEASE For immediate release Devonian Health Group announces presentation of Thykamine™ efficacy results in Atopic Dermatitis at the World Congress of Dermatology and provides Thykamine™ Clinical Development Program Update. QUEBEC, – May 16, 2023 – Devonian...